Bibliografia UJ CM

1/4
Larry W. Kwak, Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Tobias Menne, Jose Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yanez Ruiz, Marek Trneny, Leslie Popplewell, Michinori Ogura, Won-Seog Kim, Sang Joon Lee, Sung Hyun Kim, Keum Young Ahn, Christian Buske.
Efficacy and safety of CT-P10 versus rituximab in untreated low-tumor-burden follicular lymphoma : final results of a randomized phase III study.
Clinical Lymphoma, Myeloma and Leukemia
2022 : Vol. 22, nr 2, s. 89-97, il., bibliogr. 24 poz., abstr.
Autor korespondencyjny: Christian Buske.
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.
p-ISSN: 2152-2650
e-ISSN: 2152-2669
AZ
ORG
AIF
IF: 2.700
Adres url:
Streszczenie w PubMed:
2/4
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, H. Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Anne Lennard, Jose Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zharvid, Eduardo Yanez Ruiz, Marek Trneny, Leslie Popplewall, Bertrand Coiffier, Christian Buske, Won-Seog Kim, Sang Joon Lee, Sung Young Lee, Jun Ju Bae, Larry W. Kwak.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Lancet. Haematology
2018 : Vol. 5, nr 11, s. e543-e553, il., bibliogr.
Autor korespondencyjny: Larry W. Kwak.
p-ISSN: 2352-3026
AZ
ORG
AIF
IF: 11.990
Adres url:
Streszczenie w PubMed:
DOI:
3/4
Georg Hess, Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Isabelle Bence-Bruckler, Seok-Goo Cho, Wenjiong Zhou, Jenna D. Goldberg, Cristina Trambitas, Christopher Enny, Jessica Vermeulen, Shana Traina, Chiun-Fang Chiou, Joris Diels, Martin Dreyling.
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Leukemia & Lymphoma
2017 : Vol. 58, nr 12, s. 2824-2832
Autor korespondencyjny: Georg Hesss.
p-ISSN: 1042-8194
AZ
ORG
AIF
IF: 2.644
Adres url:
Streszczenie w PubMed:
DOI:
4/4
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trneny, Fritz Offner, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Georg Hess, Isabelle Bence-Bruckler, Seok-Goo Cho, John Bothos, Jenna D. Goldberg, Christopher Enny, Shana Traina, Sriram Balasubramanian, Nibedita Bandyopadhyay, Steven Sun, Jessica Vermeulen, Aleksandra Rizo, Simon Rule.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet
2016 : Vol. 387, nr 10020, s. 770-778, il., bibliogr. 29 poz., sum.
p-ISSN: 0140-6736
AZ
ORG
AIF
IF: 47.831
Adres url:
Streszczenie w PubMed:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ